Emergent BioSolutions (LTS:0IGA) EV-to-Revenue : 0.95 (As of May. 22, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Emergent BioSolutions EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Emergent BioSolutions's enterprise value is $1,099 Mil. Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $1,158 Mil. Therefore, Emergent BioSolutions's EV-to-Revenue for today is 0.95.

The historical rank and industry rank for Emergent BioSolutions's EV-to-Revenue or its related term are showing as below:

LTS:0IGA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8 Med: 3.63 Max: 6.64
Current: 0.95

During the past 13 years, the highest EV-to-Revenue of Emergent BioSolutions was 6.64. The lowest was 0.80. And the median was 3.63.

LTS:0IGA's EV-to-Revenue is ranked better than
79.73% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.335 vs LTS:0IGA: 0.95

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Emergent BioSolutions's stock price is $5.33. Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $22.41. Therefore, Emergent BioSolutions's PS Ratio for today is 0.24.

Emergent BioSolutions EV-to-Revenue Historical Data

The historical data trend for Emergent BioSolutions's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions EV-to-Revenue Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.49

3.43

1.52

1.26

0.85

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1.59	1.16	0.88	0.85	0.83

Competitive Comparison of Emergent BioSolutions's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's EV-to-Revenue falls into.

Emergent BioSolutions EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Emergent BioSolutions's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1098.842	/	1157.6
	=	0.95

Emergent BioSolutions's current Enterprise Value is $1,099 Mil.
Emergent BioSolutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,158 Mil.

Emergent BioSolutions (LTS:0IGA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Emergent BioSolutions's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.33	/	22.414
	=	0.24

Emergent BioSolutions's share price for today is $5.33.
Emergent BioSolutions's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.41.

Emergent BioSolutions EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (LTS:0IGA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (LTS:0IGA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (LTS:0IGA) Headlines

No Headlines